STOK logo

STOK
Stoke Therapeutics Inc

1,002
Mkt Cap
$2.03B
Volume
182.00
52W High
$40.22
52W Low
$8.70
PE Ratio
-11.43
STOK Fundamentals
Price
$32.49
Prev Close
$32.64
Open
$32.64
50D MA
$34.11
Beta
1.30
Avg. Volume
544,372.30
EPS (Annual)
-$0.1163
P/B
5.12
Rev/Employee
$1.08M
$1,598.60
Loading...
Loading...
News
all
press releases
Stoke Therapeutics, Inc. (STOK) Reports Q1 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +0.94% and +18.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
More News
News Placeholder
Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·6d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Lags Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +25.42% and -60.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Thursday
Stoke Therapeutics (NASDAQ:STOK) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at...
MarketBeat·10d ago
News Placeholder
Stoke Therapeutics to Host Webcast and Conference Call to Discuss First Quarter 2026 Business and Financial Updates
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·13d ago
News Placeholder
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Recommendation of "Moderate Buy" by Brokerages
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation, nine have issued a buy reco...
MarketBeat·17d ago
News Placeholder
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·27d ago
News Placeholder
Baillie Gifford & Co. Purchases New Position in Stoke Therapeutics, Inc. $STOK
Baillie Gifford & Co. purchased a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities...
MarketBeat·29d ago
News Placeholder
Stoke Therapeutics to Present at the 25th Annual Needham Virtual Healthcare Conference
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·1mo ago
News Placeholder
Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine and has a lead investigational...
Business Wire·1mo ago
<
1
2
...
>

Latest STOK News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.